13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
107 檔
25.8%
As reported in its official Q1 2025 Form 13F filing, Orbimed Advisors LLC's tracked investment portfolio stood at $5.4B with 107 total positions.
In Q1 2025, Orbimed Advisors LLC adopted a defensive or profit-taking posture, trimming 20 positions and completely liquidating 114 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SVA | Sinovac Biotech Ltd. | Stock-Other | 7.96% | +3.06% | — | |
| 2 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 7.88% | +1.73% | — | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 6.77% | -1.88% | -10.98% | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.65% | +1.30% | — | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.73% | +0.02% | — | |
| 6 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.44% | -0.80% | -27.56% | |
| 7 | SYK | Stryker CORP | Stock-Healthcare | 3.19% | -0.30% | +4.30% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.92% | -0.44% | +8.96% | |
| 9 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.65% | -0.61% | +33.76% | |
| 10 | PFE | Pfizer Inc | Stock-Healthcare | 2.63% | -1.12% | EXIT | |
| 11 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.51% | +1.33% | NEW | |
| 12 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 2.49% | -0.12% | — | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.46% | — | -0.37% | |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.23% | -0.71% | -16.72% | |
| 15 | ITGR | Integer Holdings CORP | Stock-Healthcare | 1.86% | — | +15.22% | |
| 16 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.85% | — | +5.89% | |
| 17 | NTRA | Natera Inc | Stock-Healthcare | 1.84% | +0.26% | +32.45% | |
| 18 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.83% | — | -9.84% | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 1.67% | -0.91% | -20.75% | |
| 20 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.53% | +0.38% | +52.84% | |
| 21 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.49% | — | -43.08% | |
| 22 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.45% | +0.04% | NEW | |
| 23 | CGON | Cg Oncology Inc | Stock-Other | 1.44% | -0.03% | +72.73% | |
| 24 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.33% | +0.53% | — | |
| 25 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.28% | — | +62.90% | |
| 26 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.18% | — | -10.54% | |
| 27 | SIBN | Si-bone Inc | Stock-Other | 1.15% | — | -6.77% | |
| 28 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.08% | -0.20% | — | |
| 29 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.01% | -1.03% | — | |
| 30 | NPCE | Neuropace Inc | Stock-Other | 1.00% | -0.11% | — | |
| 31 | SION | Sionna Therapeutics Inc | Stock-Other | 0.92% | -0.80% | — | |
| 32 | UPB | Upstream Bio Inc | Stock-Other | 0.83% | -0.32% | — | |
| 33 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 0.82% | — | — | |
| 34 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.80% | +0.04% | NEW | |
| 35 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.80% | -0.04% | — | |
| 36 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.76% | -0.26% | — | |
| 37 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.75% | — | — | |
| 38 | MBX | Mbx Biosciences Inc | Stock-Other | 0.70% | +1.30% | +5.00% | |
| 39 | EXK | Exact Sciences CORP | Stock-Materials | 0.70% | — | — | |
| 40 | GILD | Gilead Sciences Inc | Stock-Healthcare | 0.53% | -0.17% | EXIT | |
| 41 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.53% | -0.16% | — | |
| 42 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.50% | — | — | |
| 43 | JANX | Janux Therapeutics Inc | Stock-Other | 0.49% | -0.13% | — | |
| 44 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.48% | +0.11% | -5.00% | |
| 45 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.48% | — | — | |
| 46 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 47 | VSTM | Verastem Inc | Stock-Other | 0.41% | — | — | |
| 48 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.39% | +0.06% | NEW | |
| 49 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 50 | SCPH | Scpharmaceuticals Inc | Stock-Other | 0.38% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SVA | Sinovac Biotech Ltd. | +7.2% | — | Trim |
| 2 | EWTX | Edgewise Therapeutics Inc | +4.9% | — | Add |
| 3 | BSX | Boston Scientific CORP | +3.7% | -10.98% | Trim |
| 4 | SYK | Stryker CORP | +2.3% | +4.30% | Add |
| 5 | ISRG | Intuitive Surgical Inc | +2.1% | -27.56% | Add |
| 6 | EW | Edwards Lifesciences CORP | +1.5% | +33.76% | Add |
| 7 | NBIX | Neurocrine Biosciences Inc | +1.3% | -0.37% | Trim |
| 8 | TMO | Thermo Fisher Scientific Inc | +1% | +52.84% | Add |
| 9 | UNH | Unitedhealth Group Inc | +0.9% | +53.71% | Trim |
| 10 | SIBN | Si-bone Inc | +0.7% | -6.77% | Add |
| 11 | XENE | Xenon Pharmaceuticals Inc | +0.5% | — | Trim |
| 12 | CRNX | Crinetics Pharmaceuticals In | +0.2% | — | Trim |
| 13 | DYN | Dyne Therapeutics Inc | +0.2% | -17.32% | Add |
| 14 | SCPH | Scpharmaceuticals Inc | +0.1% | — | Add |
| 15 | CGEM | Cullinan Therapeutics Inc | +0.1% | -0.96% | Add |
| 16 | NPCE | Neuropace Inc | 0% | — | Trim |
| 17 | 430 | Terns Pharmaceuticals Inc | 0% | — | Add |
| 18 | ASNSUSD | X4 Pharmaceuticals Inc | -0.1% | -5.00% | Add |
| 19 | NXTCEUR | Nextcure Inc | -0.2% | — | Trim |
| 20 | SPRY | Ars Pharmaceuticals Inc | -0.2% | — | Trim |
| 21 | ✓ | Ikena Oncology Inc | -0.3% | — | Add |
| 22 | VRTX | Vertex Pharmaceuticals Inc | -0.3% | +5.89% | Trim |
| 23 | ORIC | Oric Pharmaceuticals Inc | -0.3% | — | Trim |
| 24 | XTNT | Xtant Medical Holdings Inc | -0.4% | — | Add |
| 25 | JANX | Janux Therapeutics Inc | -0.4% | — | Trim |
| 26 | ✓ | -0.5% | — | Trim | |
| 27 | KROS | Keros Therapeutics Inc | -0.5% | — | Trim |
| 28 | NTRA | Natera Inc | -0.5% | +32.45% | Trim |
| 29 | TORCEUR | Adicet Bio Inc | -0.5% | — | Add |
| 30 | ✓ | Passage Bio Inc | -0.9% | -5.00% | Add |
| 31 | RPTX | Repare Therapeutics Inc | -1% | — | Trim |
| 32 | XBI | Ss Spdr S&p Biotech ETF | -1.1% | -73.12% | Trim |
| 33 | ABCL | Abcellera Biologics Inc | -1.2% | — | Trim |
| 34 | ✓ | Ikena Oncology Inc | -2.2% | — | Add |
| 35 | PMVP | Pmv Pharmaceuticals Inc | -2.4% | — | Trim |
| 36 | PRLD | Prelude Therapeutics Inc | -2.7% | — | Add |
| 37 | SWTXUSD | Springworks Therapeutics Inc | -3.9% | -10.54% | Trim |
| 38 | BMY | Bristol-myers Squibb Co | — | EXIT | Sold out |
| 39 | MRK | Merck & Co. Inc. | — | EXIT | Sold out |
| 40 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 41 | ✓ | Horizon Therapeutics PLC | — | EXIT | Sold out |
| 42 | MRTXEUR | Mirati Therapeutics Inc | — | EXIT | Sold out |
| 43 | TPB | Turning Point Brands, Inc. | — | EXIT | Sold out |
| 44 | IOVA | Iovance Biotherapeutics Inc | — | EXIT | Sold out |
| 45 | ARQT | Arcutis Biotherapeutics Inc | — | EXIT | Sold out |
| 46 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 47 | GH | Guardant Health Inc | — | EXIT | Sold out |
| 48 | HUM | Humana Inc | — | EXIT | Sold out |
| 49 | ABBV | Abbvie Inc | — | EXIT | Sold out |
| 50 | ELV | Elevance Health Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 107 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SVA, EWTX, BSX) accounted for 25.8% of total reported equity market value during Q1 2025.
Top New Position Initiated
LLY
市值: $278.8M
Top Position Liquidated / Trimmed
BMY
前期市值: $301.7M
During Q1 2025, Orbimed Advisors LLC's top holdings by market value included SVA (8.0%)、EWTX (7.9%)、BSX (6.8%). The largest single position, SVA, represented 8.0% of total portfolio value.
In Q1 2025, Orbimed Advisors LLC made 200 total portfolio adjustments, initiating 49 new buys, adding to 17 positions, trimming 20 holdings, and fully liquidating 114 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.